Drug related adverse event assessment in neonates in clinical trials and clinical care-Reference-Cited by-同舟云学术

Drug related adverse event assessment in neonates in clinical trials and clinical care

Published:2024-08-13 Issue:9 Volume:17 Page:803-816
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Yalcin Nadir¹^ORCID,van den Anker John²,Samiee-Zafarghandy Samira³,Allegaert Karel⁴⁵⁶^ORCID

Affiliation:

1. Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye

2. Division of Clinical Pharmacology, Children’s National Hospital, Washington, DC, USA

3. Department of Pediatrics, Division of Neonatology, McMaster University, Hamilton, ON, Canada

4. Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

5. Department of Development and Regeneration, Leuven, Belgium

6. Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2024.2390927

Reference82 articles.

1. Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates

2. Neonatal drug therapy: The first frontier of therapeutics for children

3. Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

4. From the Food and Drug Administration. AAP News. Historic milestone: 1 000 drugs biologics have new pediatric use information in label. [cited 2024 Apr 24]. Available from: https://www.fda.gov/media/161414/download?attachment

5. Research on medication use in the neonatal intensive care unit